Genprex, Inc. (NASDAQ: GNPX) is witnessing a notable uptick in its shares following the declaration of its participation in a significant event. GNPX stock is currently experiencing a 17.76% increase, reaching $2.85 as observed in the latest market session.
Presentation At 2024 BIO International Convention
Ryan Confer, the President, Chief Financial Officer, and Chief Executive Officer of Genprex, will present a thorough summary of the company’s cutting-edge gene treatments for diabetes and cancer during a forthcoming interaction at the 2024 BIO International Convention. The San Diego Convention Center will host the Convention from June 3–6, 2024, providing Genprex with a critical venue to demonstrate its innovations.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The presentation by Mr. Confer will explain the ground-breaking gene treatments created by Genprex and is scheduled for Monday, June 3, 2024, at 2:00 p.m. PT. In addition, he will be reachable by participants one-on-one through the conference platform, offering insightful information on the efforts of the firm.
Advancements In Cancer Therapy
Genprex recently initiated the enrollment and dosing of the first patient in the Phase 1 dose escalation segment of the Acclaim-3 clinical study. This study focuses on Reqorsa (quaratusugene ozeplasmid) Immunogene Therapy, administered in combination with Genentech’s Tecentriq, aimed at treating patients with extensive-stage small cell lung cancer (ES-SCLC).
This milestone marks a significant stride in Genprex’s endeavor to combat lung cancers, particularly ES-SCLC, known for its aggressiveness and limited treatment options. The Phase 1 segment of the Acclaim-3 study aims to ascertain the maximum tolerated dose for the subsequent Phase 2 expansion study.
Building on the favorable outcomes from the Phase 1 Acclaim-1 study in non-small cell lung cancer (NSCLC), Genprex anticipates expediting the Phase 1 portion of Acclaim-3 during the latter half of 2024. This acceleration strategy aims to facilitate a swift transition into the Phase 2 expansion phase of Acclaim-3 during the same period.
Genprex’s innovative cancer treatment platform specializes in re-expressing tumor suppressor genes, crucial components often disrupted or deactivated early in the course of cancer progression.
